S05 - How Obesity Weighs-in on Management of T2D with Co-Morbid ASCVD and/or Heart Failure

Saturday, August 9, 2025

10:00 AM - 10:45 AM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE

Visceral adiposity/obesity are root causes for insulin resistance and T2D. Additionally, obesity is an independent risk factor for both atherosclerotic heart disease and heart failure. Advanced Diabetes Managers who address these co-morbid conditions must understand bi-directional relationships and the recommended pharmacological treatments to optimize care. This session discusses the ADA recommendations for disease management of those with obesity, T2D, ASCVD and/or heart failure. The presenter uses case studies to illustrate implementation into practice.

Disclosure(s):

Lucia Novak, MSN, ANP-BC, BC-ADM: Abbott Diabetes Care: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Nestle: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Primary Presenter(s)

Lucia M. Novak, MSN, ANP-BC, BC-ADM (she/her/hers)

President
Diabesity, LLC
North Bethesda, Maryland

Disclosure(s): Abbott Diabetes Care: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Nestle: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Session Host(s)

Clipper Young, PharmD, MPH, CDCES, BC-ADM, BCGP, APh, FADCES (he/him/his)

Professor and Clinical Pharmacist
Touro University California
Fairfield, California

Disclosure information not submitted.